Novogene Co., Ltd. (SHA:688315)
China · Delayed Price · Currency is CNY 13.92
+0.13 (0.94%)
Mar 30, 2026, 3:00 PM CST
Novogene Market Cap
Novogene has a market cap or net worth of 5.59 billion as of March 27, 2026. Its market cap has decreased by -20.01% in one year.
Market Cap
5.59B
Enterprise Value
4.15B
Revenue
2.17B
Ranking
n/a
PE Ratio
32.01
Stock Price
13.92
Market Cap Chart
Since April 13, 2021, Novogene's market cap has decreased from 10.97B to 5.59B, a decrease of -49.06%. That is a compound annual growth rate of -12.72%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 5.59B | 3.84% |
| Dec 31, 2025 | 5.38B | 6.24% |
| Dec 31, 2024 | 5.06B | -47.88% |
| Dec 29, 2023 | 9.71B | -8.02% |
| Dec 30, 2022 | 10.56B | -36.10% |
| Dec 31, 2021 | 16.53B | 50.73% |
| Apr 13, 2021 | 10.97B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Shenzhen Weiguang Biological Products | 6.24B |
| Xiangxue Pharmaceutical | 6.23B |
| GemPharmatech | 6.00B |
| Lifecome Biochemistry | 5.92B |
| R&G PharmaStudies | 5.91B |
| Beijing Konruns Pharmaceutical | 5.85B |
| Shanghai OPM Biosciences | 5.80B |
| Shouyao Holdings (Beijing) Co., LTD. | 5.77B |